EB-1020 (Centanafadine) 164.4 mg

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Attention Deficit Hyperactivity Disorder (ADHD)

Drug Information

Target Indication

Attention Deficit Hyperactivity Disorder (ADHD)

Clinical Trial

Last updated: 12/13/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

OTSKF

OTSUKA

Related Pipeline

Schizophrenia

Agitation Associated With

Attention-deficit/Hyperactivity Disorder

Phenylketonuria (PKU)

Attention Deficit/Hyperactivity Disorder

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts